BAT Releases 2024 Fiscal Year Trading Update on December 11th

Dec.11.2024
BAT Releases 2024 Fiscal Year Trading Update on December 11th
BAT announces strong growth in new product categories and traditional tobacco revenues for the second half of 2024 fiscal year.

On December 11, British American Tobacco (BAT) released a trading update for the fiscal year ending 2024. The company stated that the accelerated growth in the second half of 2024 was in line with expectations, primarily driven by innovation in new product categories. Revenue from new product categories and traditional tobacco is expected to increase in the second half of the year compared to the first half.


BAT expects that by the end of 2024, the cash conversion rate will exceed 90%, while the leverage ratio will be within the target range of 2.0-2.5 times. Additionally, they have expressed support for the Canadian Companies' Creditors Arrangement Act (CCAA) and are hopeful to reach a conclusion that is beneficial for all stakeholders.


In the traditional tobacco industry, the United States' business actions continued to gain momentum in the second half of the year; in the AME and APMEA regions, its market share continued to grow. Investments in the first half of the year in the US business actions and wholesale inventory adjustments drove an increase in organic sales volume and financial performance in the traditional tobacco business in the second half of the year. Despite a slight decrease in value share due to the impact of the US market's geographic mix, volume share increased by 20 basis points in key markets.


The performance of new business categories is also improving. Vuse e-cigarettes maintain a leading market share globally, with a 40.3% share in key markets (50.7% share in tracked channels in the U.S.). Meanwhile, the innovative product line of the glo brand is showing signs of accelerated growth in the second half of the year, with new products like glo Hyper Pro driving sales growth. The Velo brand continues to experience strong growth in markets outside the U.S., solidifying its position as a leader in the oral market.


BAT expects a decrease in sales of approximately 2% in 2024, with organic revenue and profit growth forecasted to be in the low single digits. Planned capital expenditure is around 600 million pounds, and net financial expenses are expected to be 1.6 billion pounds, impacted by fluctuations in exchange rates and interest rates.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Product | GEEKBAR MATE 60K Launches in U.S. Channels With 15ml E-Liquid and Up to 60,000 Puffs
Product | GEEKBAR MATE 60K Launches in U.S. Channels With 15ml E-Liquid and Up to 60,000 Puffs
E-cigarette brand GEEKBAR has recently launched its new product, the GEEKBAR MATE 60K, on its official website. The product adopts a pod-based system, consisting of a reusable 900mAh device and a pod prefilled with 15ml of e-liquid and equipped with a built-in 200mAh battery, bringing the total battery capacity to 1100mAh. It supports both Regular and Pulse modes.
Mar.30 by 2FIRSTS.ai
RJR Vapor Loses Tax Refund Case as Texas High Court Finds VELO Pouches Taxable
RJR Vapor Loses Tax Refund Case as Texas High Court Finds VELO Pouches Taxable
The Texas Supreme Court issued a case summary on May 8, 2026, describing its decision in Hancock v. RJR Vapor Co. LLC. The dispute centered on whether RJR Vapor’s VELO oral nicotine pouches are taxable as “tobacco products” under the Texas Tax Code. Lower courts had held that the pouches were not taxable tobacco products, but the Texas Supreme Court reversed, concluding that VELO pouches are taxable because they are made of “a tobacco substitute.”
May.09 by 2FIRSTS.ai
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas Says FDA Scientific Review Backed Several Flavored Products Before Senior Leaders Blocked Them
Glas says newly released internal FDA records show agency scientific reviewers supported authorization for several flavored G2 products before senior leadership halted them. According to documents obtained through a Freedom of Information Act request, FDA’s Office of Science first recommended marketing authorization for all eight products in December 2025 and later supported six of them in February 2026. FDA ultimately authorized only the G2 device and one tobacco-flavored pod in March.
Apr.23 by 2FIRSTS.ai
Cross-Party Romanian Lawmakers Propose Ban on E-Cigarettes and Heated Tobacco Use in All Enclosed Public Spaces
Cross-Party Romanian Lawmakers Propose Ban on E-Cigarettes and Heated Tobacco Use in All Enclosed Public Spaces
Lawmakers from Romania’s USR, PSD and PNL have submitted a bill that would ban e-cigarettes, vapes and heated tobacco devices in all enclosed public spaces. The proposal would redefine “smoking” so that inhaling aerosols produced by heating or vaporizing products containing tobacco, nicotine or other substances intended for inhalation would also be considered smoking, except for medical-use products.
Apr.17 by 2FIRSTS.ai
West Virginia Bill Would Direct USD 2.9 Million of Juul Settlement to Youth Tobacco and Vaping Prevention
West Virginia Bill Would Direct USD 2.9 Million of Juul Settlement to Youth Tobacco and Vaping Prevention
A bill completed during West Virginia’s 2026 regular legislative session would make a one-time allocation of USD 2.9 million from the state’s USD 7.9 million settlement with Juul to youth tobacco prevention and cessation programs.
Mar.19 by 2FIRSTS.ai
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
FDA Launches Elsa 4.0 and Completes HALO Data Platform Consolidation
The U.S. Food and Drug Administration announced on May 6 that it has advanced its modernization initiative by launching Elsa 4.0, an upgraded internal AI tool, and consolidating more than 40 application and submission data sources, systems and portals into a new platform called HALO. FDA said the integration of HALO and Elsa will allow staff to query data and build workflows without manually uploading documents in each chat.
May.07 by 2FIRSTS.ai